Novelix Pharmaceuticals Inc is a private California-based biotechnology company committed to developing proprietary first-in-class targeted small molecules for cancer therapy. The company achieved profitability in 2006, its second year of operations, became a clinical stage animal health company and successfully completed a human pilot on one of its lead drug candidates. All of Novelixâ small molecule drugs and platforms have been designed and created by the companyâs founders. The founders have worked closely with each other on related ventures over the last 15 years. Beyond its innovative compounds and experienced team, the company differentiates itself through a business model that reduces risk by evaluating its drug candidates not only in commonly used model systems but also in canine patients with spontaneously occuring tumors that more closely resemble human cancer. Novelix maximizes shareholder value by proactively pursuing early licensing opportunities. Novelix has selected three lead product c
